WO2012085304A1 - Composición farmacéutica de fosfomicina - Google Patents
Composición farmacéutica de fosfomicina Download PDFInfo
- Publication number
- WO2012085304A1 WO2012085304A1 PCT/ES2011/000366 ES2011000366W WO2012085304A1 WO 2012085304 A1 WO2012085304 A1 WO 2012085304A1 ES 2011000366 W ES2011000366 W ES 2011000366W WO 2012085304 A1 WO2012085304 A1 WO 2012085304A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- composition according
- total weight
- fosfomycin
- glycine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention relates to a stable pharmaceutical composition for oral administration of the antibiotic fosfomycin.
- Phosphomycin tromethamine whose chemical name is mono (2-ammonium-2-hydroxymethyl-l, 3-propanediol) (2R, cis) - (3-methyloxyranyl) phosphonate, is an antibiotic indicated for prophylaxis and Treatment of uncomplicated acute infections of the lower urinary tract.
- Various pharmaceutical compositions of fosfomycin trometamol for oral administration are disclosed in the state of the art.
- Spanish patent application ES495870 (Zambón, Spa) describes a composition for oral administration in the form of sachets containing phosphomycin tromethamine, sodium carboxymethyl cellulose, lactose, titanium dioxide, orange aroma and sucrose.
- the sucrose content in this composition depending on the dose of active ingredient, varies between 56 and 76% expressed by weight with respect to the total weight of the composition.
- Another Spanish patent application, ES2020790 discloses a granulate containing fosfomycin tromethamine, saccharin, flavor and sucrose.
- the sucrose content in this composition comprises 28% expressed by weight with respect to the total weight of the composition.
- Spanish patent application ES2224869 (Zambón Group, Spa) discloses the use of certain basic compounds to stabilize a pharmaceutical composition of fosfomycin trometamol. Some of the compositions described in the examples also They mention the use of between 16% and 22% sucrose expressed by weight with respect to the total weight of the composition.
- Spanish patent application ES2244333 (Simbec Ibérica, S.L.) discloses a pharmaceutical preparation comprising fosfomycin tromethamine, mannitol and / or xylitol and an artificial sweetener chosen from the group including acesulfame, aspartame, saccharin, alitame and / or cyclamate.
- the content of mannitol and / or xylitol comprises between 20-40% expressed by weight with respect to the total weight of the composition.
- sugars such as sucrose, fructose or glucose
- a pharmaceutical composition of fosfomycin tromethamine may result in an unwanted coloration due to the reaction of the aldehyde groups of said sugars with the tromethamine amine or with any other primary amino group present in the composition.
- the presence of these sugars means that the pharmaceutical composition obtained is not suitable for administration to diabetic patients.
- compositions comprising a sugar derivative such as a sugar alcohol, in particular xylitol, mannitol, sorbitol or mixtures thereof, can cause intestinal problems such as a laxative effect. Unwanted or abdominal gas.
- the present invention relates to a stable solid pharmaceutical composition of phosphomine for oral administration characterized in that it comprises fosfomycin tromethamine, glycine, optionally other pharmaceutically acceptable excipients, and is substantially free of sugars and sugar alcohols such as sucrose, fructose, glucose, xylitol, mannitol, sorbitol or mixtures thereof.
- sugars and sugar alcohols such as sucrose, fructose, glucose, xylitol, mannitol, sorbitol or mixtures thereof.
- substantially free means that the sugar or sugar alcohol content is nonexistent or so low that the pharmaceutical composition of fosfomycin of the invention remains stable against coloration, suitable for diabetics and does not cause intestinal problems.
- Glycine is a neutral amino acid with a pH value between 5.9 and 6.4 according to the European Pharmacopeia 6.0. Glycine has no side chain; It is the only amino acid without chiral center.
- This amino acid has a slight sweet taste that, unlike other bitter or acidic amino acids, makes it suitable for use as a diluent in a pharmaceutical composition for oral administration. Additionally, the absence of aldehyde groups in its structure prevents coloration due to the reaction of Maillard with amines allowing stable compositions to be obtained against coloration. At the same time, a pharmaceutical composition comprising glycine does not pose a risk to diabetic patients since it does not give rise to a glycemic response, and does not cause gastrointestinal problems such as an unwanted laxative effect or abdominal gas.
- the amount of glycine can easily be determined by one skilled in the art to obtain an oral solid pharmaceutical composition of fosfomycin trometamol by known techniques common in the state of the art.
- the amount of glycine present in the pharmaceutical composition of fosfomycin may comprise between 0.1% and 70% expressed by weight with respect to the total weight of the composition.
- the amount of glycine comprises between 20 and 50% by weight with respect to the total weight of the composition.
- this pharmaceutical composition of fosfomycin trometamol comprises one or more sweeteners to improve its palatability.
- the sweetener is chosen from the group that includes sucralose, acesulfame, aspartame, saccharin, al-tamo, cyclamate, neohesperidine dihydrocalcone, thaumatine and mixtures thereof. More preferably, the sweetener used to improve the palatability of the pharmaceutical composition comprising fosfomycin tromethamine and glycine is sucralose. This compound is 300 to 1000 times sweeter than sucrose, it has no aftertaste characteristic of other artificial sweeteners, it is not absorbed by the body and does not present toxicity problems.
- the addition of sucralose to the pharmaceutical composition makes it possible to obtain a more pleasant flavor composition using only a small amount of said sweetener.
- the pharmaceutical composition of fosfomycin tromethamine and glycine of this invention may comprise between 0.0 and 5.0% sucralose, preferably between 1.0 and 2.0% expressed by weight with respect to the total weight of the composition.
- the pharmaceutical composition of fosfomycin is presented as a powder or granules for solution. More preferably the powder or granules for solution are contained in single dose envelopes for solution.
- the pharmaceutical composition of fosfomycin further comprises one or more pharmaceutically acceptable excipients customary in the pharmaceutical industry to obtain solid compositions for oral administration, in particular to obtain pharmaceutical compositions in the form of powder or granules for solution.
- these excipients are chosen from the group that includes sliders such as calcium silicate, magnesium silicate, silicon dioxide, magnesium stearate, magnesium oxide, talcum, cellulose, starch or mixtures thereof; binders such as microcrystalline cellulose, pregelatinized starch, copovidone, polyvinyl pyrrolidone (povidone), hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydrogenated vegetable oil or mixtures thereof; and / or flavorings such as aroma of orange, tangerine, lemon, raspberry, strawberry or coconut.
- the pharmaceutical composition of the invention further comprises silicon dioxide as a slider, polyvinylpyrrolidone as a binder and lemon flavor.
- the pharmaceutical composition of this invention generally contains between 1.9 and 7.5 g of fosfomycin trometamol, which corresponds to 1.0 and 4.0 g of fosfomycin expressed as free acid.
- the composition contains between 3.8 g and 5.6 g of fosfomycin trometamol, which corresponds to 2.0 and 3.0 g of fosfomycin expressed as free acid.
- the amounts of active substance mentioned above correspond to between
- the stable solid pharmaceutical composition of fosfomycin for oral administration of this invention can be used for the manufacture of a medicament for the treatment or prophylaxis of uncomplicated acute infections of the lower urinary tract.
- the stable solid pharmaceutical composition of fosfomycin for oral administration of this invention can be used for the treatment or prophylaxis of uncomplicated acute infections of the lower urinary tract.
- the pharmaceutical composition of fosfomycin of this invention can be obtained by methods widely known to those skilled in the art, in particular by mixing and / or granulation methods.
- the components are mixed homogeneously and, optionally, are granulated by standard techniques in the state of the art.
- the solid obtained is dosed in sachets containing the amount equivalent to 2.0 g or 3.0 g of acidic fosfomycin.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201390760A EA023846B1 (ru) | 2010-12-24 | 2011-12-19 | Фармацевтическая композиция фосфомицина |
MX2013007232A MX342938B (es) | 2010-12-24 | 2011-12-19 | Composicion farmaceutica de fosfomicina. |
ES11851679.8T ES2574916T3 (es) | 2010-12-24 | 2011-12-19 | Composición farmacéutica de fosfomicina |
CN201180062697.XA CN103282038B (zh) | 2010-12-24 | 2011-12-19 | 磷霉素药物组合物 |
EP11851679.8A EP2656846B1 (en) | 2010-12-24 | 2011-12-19 | Phosphomycin pharmaceutical composition |
JP2013545445A JP6012622B2 (ja) | 2010-12-24 | 2011-12-19 | ホスホマイシン医薬組成物 |
DK11851679.8T DK2656846T3 (en) | 2010-12-24 | 2011-12-19 | Pharmaceutical phosphomycinsammensætning |
BR112013016029A BR112013016029A2 (pt) | 2010-12-24 | 2011-12-19 | composição farmacêutica de fosfomicina. |
KR1020137016662A KR20140091649A (ko) | 2010-12-24 | 2011-12-19 | 포스포마이신 약학적 조성물 |
CA2821382A CA2821382C (en) | 2010-12-24 | 2011-12-19 | Phosphomycin pharmaceutical composition |
HK14102180.0A HK1188959A1 (zh) | 2010-12-24 | 2014-03-04 | 磷霉素藥物組合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP201001613 | 2010-12-24 | ||
ES201001613A ES2385158B1 (es) | 2010-12-24 | 2010-12-24 | Composición farmacéutica de fosfomicina |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012085304A1 true WO2012085304A1 (es) | 2012-06-28 |
Family
ID=46313210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2011/000366 WO2012085304A1 (es) | 2010-12-24 | 2011-12-19 | Composición farmacéutica de fosfomicina |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP2656846B1 (es) |
JP (1) | JP6012622B2 (es) |
KR (1) | KR20140091649A (es) |
CN (1) | CN103282038B (es) |
BR (1) | BR112013016029A2 (es) |
CA (1) | CA2821382C (es) |
DK (1) | DK2656846T3 (es) |
EA (1) | EA023846B1 (es) |
ES (2) | ES2385158B1 (es) |
HK (1) | HK1188959A1 (es) |
HU (1) | HUE027572T2 (es) |
MX (1) | MX342938B (es) |
PL (1) | PL2656846T3 (es) |
PT (1) | PT2656846T (es) |
WO (1) | WO2012085304A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017111718A1 (en) | 2015-12-25 | 2017-06-29 | Yusuf Toktamiş Öğün | The formulation comprising phosphomycine and ascorbic acid for the treatment of bacterial urinary system infections |
CA3147662A1 (en) | 2021-02-10 | 2022-08-10 | Labiana Health, S.L. | New fosfomycin tablet formulations |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4727065A (en) * | 1978-07-19 | 1988-02-23 | Zambon S.P.A. | Bis-(2-ammonium-2-hydroxymethyl-1,3-propanediol(2R-cis)-(3-methyloxiranyl)-phosphonate, a method of preparing same, and pharmaceutical compositions containing same |
ES2020790A6 (es) | 1989-07-27 | 1991-09-16 | Zambon Spa | Un procedimiento para la preparacion de mono-(2-monio-2-hidroximetil-1,3-propandiol)(2r,cis)-epoxipropil-fosfonato. |
ES2103682B1 (es) * | 1995-09-20 | 1998-04-01 | Lilly Sa | Composicion farmaceutica oral de fluoxetina, solida y con caracteristicas organolepticas mejoradas. |
ES2224869A1 (es) | 2002-08-01 | 2005-03-01 | Zambon Group S.P.A. | Composiciones farmaceuticas con actividad antibiotica. |
ES2244333A1 (es) | 2004-05-18 | 2005-12-01 | Simbec Iberica, Sl | Preparado farmaceutico oral de fosfomicina estable y apto para diabeticos. |
-
2010
- 2010-12-24 ES ES201001613A patent/ES2385158B1/es active Active
-
2011
- 2011-12-19 EP EP11851679.8A patent/EP2656846B1/en active Active
- 2011-12-19 JP JP2013545445A patent/JP6012622B2/ja not_active Expired - Fee Related
- 2011-12-19 ES ES11851679.8T patent/ES2574916T3/es active Active
- 2011-12-19 KR KR1020137016662A patent/KR20140091649A/ko not_active Application Discontinuation
- 2011-12-19 EA EA201390760A patent/EA023846B1/ru not_active IP Right Cessation
- 2011-12-19 PT PT118516798T patent/PT2656846T/pt unknown
- 2011-12-19 DK DK11851679.8T patent/DK2656846T3/en active
- 2011-12-19 CN CN201180062697.XA patent/CN103282038B/zh not_active Expired - Fee Related
- 2011-12-19 HU HUE11851679A patent/HUE027572T2/en unknown
- 2011-12-19 PL PL11851679.8T patent/PL2656846T3/pl unknown
- 2011-12-19 MX MX2013007232A patent/MX342938B/es active IP Right Grant
- 2011-12-19 CA CA2821382A patent/CA2821382C/en not_active Expired - Fee Related
- 2011-12-19 WO PCT/ES2011/000366 patent/WO2012085304A1/es active Application Filing
- 2011-12-19 BR BR112013016029A patent/BR112013016029A2/pt not_active Application Discontinuation
-
2014
- 2014-03-04 HK HK14102180.0A patent/HK1188959A1/zh not_active IP Right Cessation
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4727065A (en) * | 1978-07-19 | 1988-02-23 | Zambon S.P.A. | Bis-(2-ammonium-2-hydroxymethyl-1,3-propanediol(2R-cis)-(3-methyloxiranyl)-phosphonate, a method of preparing same, and pharmaceutical compositions containing same |
ES2020790A6 (es) | 1989-07-27 | 1991-09-16 | Zambon Spa | Un procedimiento para la preparacion de mono-(2-monio-2-hidroximetil-1,3-propandiol)(2r,cis)-epoxipropil-fosfonato. |
US5162309A (en) * | 1989-07-27 | 1992-11-10 | Zambon Group | Mono (2-ammonium-2-hydroxymethyl-1,3-propanediol)(2r,cis)-1,2-ep-oxipropyl-phosphonate with improved characteristics of stability and processing |
ES2103682B1 (es) * | 1995-09-20 | 1998-04-01 | Lilly Sa | Composicion farmaceutica oral de fluoxetina, solida y con caracteristicas organolepticas mejoradas. |
ES2224869A1 (es) | 2002-08-01 | 2005-03-01 | Zambon Group S.P.A. | Composiciones farmaceuticas con actividad antibiotica. |
ES2224869B1 (es) * | 2002-08-01 | 2007-07-01 | Zambon Group S.P.A. | Composiciones farmaceuticas con actividad antibiotica. |
ES2244333A1 (es) | 2004-05-18 | 2005-12-01 | Simbec Iberica, Sl | Preparado farmaceutico oral de fosfomicina estable y apto para diabeticos. |
ES2244333B1 (es) * | 2004-05-18 | 2006-08-01 | Simbec Iberica, Sl | Preparado farmaceutico oral de fosfomicina estable y apto para diabeticos. |
Non-Patent Citations (1)
Title |
---|
See also references of EP2656846A4 * |
Also Published As
Publication number | Publication date |
---|---|
HUE027572T2 (en) | 2016-10-28 |
PL2656846T3 (pl) | 2016-09-30 |
EA023846B1 (ru) | 2016-07-29 |
CN103282038B (zh) | 2016-08-10 |
EP2656846A1 (en) | 2013-10-30 |
ES2385158B1 (es) | 2013-05-28 |
JP6012622B2 (ja) | 2016-10-25 |
DK2656846T3 (en) | 2016-07-04 |
MX342938B (es) | 2016-10-19 |
CA2821382A1 (en) | 2012-06-28 |
ES2385158A1 (es) | 2012-07-19 |
KR20140091649A (ko) | 2014-07-22 |
EA201390760A1 (ru) | 2013-12-30 |
BR112013016029A2 (pt) | 2017-06-13 |
ES2574916T3 (es) | 2016-06-23 |
HK1188959A1 (zh) | 2014-05-23 |
CN103282038A (zh) | 2013-09-04 |
EP2656846B1 (en) | 2016-03-30 |
MX2013007232A (es) | 2013-08-15 |
EP2656846A4 (en) | 2014-07-09 |
PT2656846T (pt) | 2016-07-08 |
CA2821382C (en) | 2019-01-08 |
JP2014500301A (ja) | 2014-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2241460C2 (ru) | Фармацевтическая композиция цефуроксим аксетила с маскированным горьким вкусом | |
EP2005945A2 (en) | Oseltamivir phosphate granule and preparation mehtod thereof | |
ES2700251T3 (es) | Composición farmacéutica de ibuprofeno, tramadol y un aminoácido básico, procedimiento para su preparación y utilización de la misma | |
EP3003384A1 (en) | Oral solution comprising atomoxetine hydrochloride | |
ES2340779T3 (es) | Preparado farmaceutico oral de fosfomicina estable y apto para diabeticos. | |
CA2891362C (en) | Effervescent tablet | |
WO2012093972A1 (en) | Water soluble dosage forms | |
ES2574916T3 (es) | Composición farmacéutica de fosfomicina | |
US8604078B2 (en) | Fosfomycin pharmaceutical composition | |
TW201818921A (zh) | 乙醯胺酚及曲馬多共溶複方止痛口服液 | |
US20220218606A1 (en) | Ready to use diclofenac stick packs | |
WO2012150607A2 (en) | Oral liquid composition comprising divalproex sodium and process for preparing thereof | |
GR1009069B (el) | Ποσιμα διαλυματα υψηλης συγκεντρωσης που περιεχουν υδροχλωρικη ρανιτιδινη | |
KR20230022941A (ko) | 생체이용성 당-기반 디클로페낙 제형 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11851679 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2821382 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2013545445 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/007232 Country of ref document: MX Ref document number: 201390760 Country of ref document: EA Ref document number: 2011851679 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20137016662 Country of ref document: KR Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013016029 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013016029 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130621 |